The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Description of Evidence ¹

Added text ² to state that the incidence of breast cancer is lower in patients using selective estrogen receptor modifiers, but it is too early to observe an impact on breast cancer mortality.

Added text ³ about the Raloxifene Use for the Heart trial, which was a randomized, placebo-controlled trial to evaluate the effects of raloxifene on incidence of coronary events and invasive breast cancer.